Vnitr Lek 2021, 67(3):e03-e07 | DOI: 10.36290/vnl.2021.043

Rituximab in the treatment of primary glomerulopathies - our experience

Karol Graňák1, Matej Vnučák1, Margaréta Pytliaková2, Ľudovít Laca1, Marián Mokáň3, Ivana Dedinská1
1 Chirurgická klinika a Transplantačné centrum, Univerzitná nemocnica Martin a Jesseniova lekárska fakulta Univerzity Komenského
2 Klinika anesteziológie a intenzívnej medicíny, Univerzitná nemocnica Martin a Jesseniova lekárska fakulta Univerzity Komenského
3 I. interná klinika, Univerzitná nemocnica Martin a Jesseniova lekárska fakulta Univerzity Komenského

Úvod: Od roku 2012, keď iniciatíva "The Kidney Disease: Improving Global Outcomes publikovala prvé odporúčania pre manažment a liečbu glomerulárnych chorôb, došlo k enormnému pokroku v porozumení patogenézy, identifikácii nových diagnostických biomarkerov a liečbe týchto ochorení. Rituximab sa stal liečebnou možnosťou so sľubným efektom u pacientov s primárnymi chorobami glomerulov, čo potvrdzujú viaceré klinické štúdie, kde viedol k významnej redukcii proteinúrie a zníženiu incidencie relapsov základného ochorenia. V práci prezentujeme naše skúsenosti s liečbou rituximabom.

Keywords: primary glomerulopathy, proteinuria, rituximab.

Published: May 26, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Graňák K, Vnučák M, Pytliaková M, Laca Ľ, Mokáň M, Dedinská I. Rituximab in the treatment of primary glomerulopathies - our experience. Vnitr Lek. 2021;67(3):e03-07. doi: 10.36290/vnl.2021.043.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Floege J, Barbour SJ, Cattran DC et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 95(2): 268-280. Go to original source... Go to PubMed...
    2. Rojas-Rivera JE, Carriazo S, Ortiz A. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Clin Kidney J. 2019; 12(5): 629-638. Go to original source... Go to PubMed...
    3. Fervenza FC, Appel GB, Barbour SJ et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019; 381(1): 36-46. Go to original source... Go to PubMed...
    4. Troyanov S, Wall CA, Miller JA et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004; 66: 1199-1205. Go to original source... Go to PubMed...
    5. Beck LH jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21. Go to original source... Go to PubMed...
    6. Tomas NM, Beck LH jr, Meyer-Schwesinger C et al. Trombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Eng J Med 2014; 371: 2277-2287. Go to original source... Go to PubMed...
    7. Kidney Disease: Improving Global Outcome (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 139-274.
    8. Alfaadhel T, Cattran D. Management of membranous nephropathy in Western countries. Kidney Dis (Basel) 2015; 1: 126-137. Go to original source... Go to PubMed...
    9. Rudnicki M. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies. Biomed Res Int. 2017; 2017: 2180508. Go to original source... Go to PubMed...
    10. Beaudreuil S, Lorenzo HK, Elias M et al. Optimal management of primary focal segmental glomerulosclerosis in adults. Int J Nephrol Renovasc Dis. 2017; 10: 97-107. Go to original source... Go to PubMed...
    11. Uffing A, Pérez-Sáez MJ, Mazzali M et al. Recurrence of FSGS after Kidney Transplantation in Adults. Clin J Am Soc Nephrol. 2020; 15(2): 247-256. Go to original source... Go to PubMed...
    12. Němec P. Rituximab (MabThera®) - nový biologický lék v terapii revmatoidní artritidy. Vnitr Lek 2007; 53(11): 1199-1210. Go to PubMed...
    13. Dahan K, Debiec H, Plaisier E et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017; 28(1): 348-358. Go to original source... Go to PubMed...
    14. Rojas-Rivera J, Fernández-Juárez G, Ortiz A et al. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary Membranous Nephropathy: the STARMEN study. Clin Kidney J 2015; 8: 503-510. Go to original source... Go to PubMed...
    15. Scolari F. Rituximab versus steroids and cyclophosphamide in the treatment of idiopathic membranous nephropathy (RI-CYCLO) https://clinicaltrials.gov/ct2/show/NCT03018535 (6 August 2019, date last accessed).
    16. Tsagalis G, Psimenou E, Nakopoulou L et al. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs. 2011; 35(4): 420-425. Go to original source... Go to PubMed...
    17. Cho JH, Lee JH, Park GY et al. Successful treatment of recurrent focal segmental glomerulosclerosis with a low dose rituximab in a kidney transplant recipient. Ren Fail. 2014; 36(4): 623-626. Go to original source... Go to PubMed...
    18. Goswami RP, Sircar G, Sit H et al. Cyclophosphamide versus mycophenolate versus rituximab in lupus nephritis remission induction. JCR: Journal of Clinical Rheumatology. J Clin Rheumatol. 2019; 25(1): 28-35. Go to original source... Go to PubMed...
    19. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-Associated vasculitis. N Engl J Med. 2010; 363(3): 221-232. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.